Karen Naim

Pfizer (United States)

Papers

1

Total Citations

86

H-Index

1

About

Dr. Karen Naim is a leading voice in pharmacovigilance innovation, specializing in the integration of artificial intelligence and automation to transform drug safety monitoring. Her most cited work, "Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing" (2018, 86 citations), demonstrates her pioneering role in demonstrating how AI and robotic process automation can streamline adverse event case processing—the most significant cost driver in pharmaceutical safety. By piloting these technologies, Dr. Naim provided critical evidence that automation can enhance efficiency, accuracy, and scalability in pharmacovigilance operations. Her contributions have helped shift the industry toward data-driven, cost-effective safety surveillance, influencing both regulatory practices and corporate strategies. With a career focused on bridging technology and patient safety, Dr. Naim continues to shape the future of pharmacovigilance, making her work essential reading for researchers and professionals seeking to modernize drug safety frameworks.

Research Focus

Key Achievements

1
H-Index
1
Papers
86
Total Citations
86
Avg Citations/Paper
🏆 Most Cited Paper
Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
86 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago